| Similar Articles |
 |
The Motley Fool January 19, 2006 Stephen D. Simpson |
Novartis Marches On While reported profits are masked by some charges, this Swiss drug company is still delivering the goods. Throw in a solid pipeline and a reasonable valuation, and the stock could still be worth a look for new money in the pharmaceutical space.  |
Chemistry World November 6, 2013 Laura Howes |
Novartis to shut Horsham site Last year, the firm slammed the UK for the high cost of conducting clinical trials in the country, warning that business would leave unless more incentives were introduced to encourage firms to carry out R&D.  |
The Motley Fool April 21, 2005 Stephen D. Simpson |
Novartis' Triple Threat The Swiss drug giant boasts strong franchises in generics, cardiology, and oncology. It's hard not to think of Novartis as one of the highest-quality options in the pharmaceutical investing space.  |
The Motley Fool October 23, 2006 Brian Lawler |
No Slowing Novartis The Swiss pharmaceutical company shows strength in nearly all its divisions. Novartis looks like a good investment for risk-adverse investors searching for a large-cap pharma stock.  |
The Motley Fool January 29, 2009 Brian Orelli |
Novartis: Diversification Isn't Good Enough Novartis has become a better diversified company, with acquisitions of vaccines specialist Chiron and 25% of eye-care specialist Alcon, but it's far from a cure all, as the fourth quarter showed.  |
The Motley Fool July 15, 2005 Stephen D. Simpson |
Novartis' Over-the-Counter Tonic Novartis' latest purchase suggests a commitment to making itself a well-rounded pharma giant. Future margins may not be as high as they once were, but if the company can produce a lot more cash flow, investors won't mind a bit.  |
The Motley Fool June 6, 2008 Brian Lawler |
Nothing Can Stop Novartis! Swiss pharmaceutical giant Novartis has bucketloads of cash, and apparently, it isn't afraid to use them.  |
The Motley Fool January 22, 2007 Brian Lawler |
Another Busy Year in Store for Novartis Trying to place a value on Novartis is a tough thing to do now with so many important drugs awaiting regulatory review and its addiction to acquisitions and divestitures making financial comparisons between the years tough.  |
The Motley Fool July 17, 2006 Stephen D. Simpson |
Novartis Pays for Its Shopping Spree Expenses from the Chiron acquisition bring down results for the second quarter. Investors, there's a lot to be said for waiting on the right price for even the best stocks out there.  |
The Motley Fool July 14, 2005 Stephen D. Simpson |
These Swiss Don't Miss Aside from a hiccup in margins, Novartis' drug business continues to shine. This pharma is a solid middle-of-the-road play with reasonable valuation, a solid pipeline, and a not-so-secret weapon in its Sandoz generics business.  |
The Motley Fool July 16, 2009 Brian Orelli |
A Strong Dollar Can Hurt Novartis makes it through a hard quarter.  |
The Motley Fool October 22, 2007 Brian Lawler |
No Catastrophes at Novartis Novartis stays on track with its third-quarter results. Investors, take note.  |
Chemistry World November 14, 2013 Phillip Broadwith |
Novartis sells off blood diagnostics division Swiss-based company Novartis has agreed to sell off its blood transfusion diagnostics unit to Spanish blood products specialist Grifols for $1.7 billion.  |
The Motley Fool September 1, 2005 Stephen D. Simpson |
Novartis Keeps Gorging Offering to buy the remainder of Chiron for $4.5 billion may up this company's execution risk over the next few quarters. Investors, take note.  |
Pharmaceutical Executive November 1, 2006 Joanna Breitstein |
Back Page: The Case for Diversity Variety is the spice of life - and the future of Big Pharma.  |
The Motley Fool July 21, 2004 Brian Gorman |
Novartis Shows the Way It may be a model for other pharmaceutical outfits looking to improve productivity.  |
The Motley Fool July 16, 2010 Brian Orelli |
A Positive Sign for Pharma Earnings Season Strong first-half results drove Novartis to increase its sales guidance for the year.  |
The Motley Fool October 21, 2008 Brian Orelli |
Novartis Is Taking the Road Less Traveled Diversification should pay off for this pharma giant.  |
The Motley Fool July 28, 2011 Melly Alazraki |
J&J or Novartis? Novartis' businesses are an investor's delight; J&J's improving but isn't there yet.  |
The Motley Fool September 20, 2005 Brian Gorman |
Novartis Stays Focused New developments at the drug giant suggest the company is on track. Investors, take note.  |
The Motley Fool January 20, 2005 Stephen D. Simpson |
Novartis Posts a Swiss Miss The Swiss drug giant has a strong pipeline, but moderate growth and high valuation suggest little room for error.  |
The Motley Fool April 25, 2007 Brian Lawler |
Nothing Wrong With Novartis Novartis releases first-quarter financial results. Investors, take note.  |
Chemistry World October 1, 2013 Emma Stoye |
Japan confirms Novartis clinical trial data fabrication Japan's ministry of health has concluded that studies based on clinical trials for Novartis's blood pressure drug Diovan contain manipulated data. It is now investigating whether the company has broken Japanese law by citing these studies to promote the product.  |
The Motley Fool January 4, 2010 Brian Orelli |
You Don't Need Your Contacts In to See This Deal Novartis acts first to grab the rest of Nestle's stake in Alcon.  |
The Motley Fool October 31, 2005 Rich Duprey |
Chiron Not Immune to Merger The board accepts a sweetened buyout offer from Swiss pharmaceutical firm Novartis. Investors, take note.  |
The Motley Fool October 18, 2005 Stephen D. Simpson |
More Good News From Novartis This Swiss drug giant continues to post steady growth. Investors, take note.  |
The Motley Fool February 22, 2005 Brian Gorman |
Novartis Embraces Generics The company is taking a different path from its branded pharmaceutical peers. The company's strategy may make its stock worth a closer look.  |
Pharmaceutical Executive November 1, 2008 |
No Ordinary Joe It's been a year since consumer marketing master Joe Jimenez took over the top spot at Novartis Pharma. How's he faring?  |
The Motley Fool January 27, 2010 Brian Orelli |
Nice, Novartis, Very Nice CEO Daniel Vasella leaves on a high note.  |
The Motley Fool April 8, 2008 Brian Lawler |
Novartis Sees More Growth Ahead Novartis makes one of the largest acquisitions in health-care history.  |
Chemistry World May 21, 2009 Matt Wilkinson |
Big Pharma set for generics boost Pharmaceutical firms have been rushing to ensure they minimize their losses by expanding their generics businesses and reach into emerging markets.  |
BusinessWeek February 4, 2010 Dermot Doherty |
The New Man at Novartis CEO Joe Jimenez says his consumer-products background, with stints at Clorox and Heinz, will be a booster for the drugmaker.  |
Chemistry World June 10, 2013 Phillip Broadwith |
Sandoz manufacturing woes continue Sandoz, the generic drugs arm of Swiss firm Novartis, has had an official warning from the US Food and Drug Administration over failings at one of its manufacturing plants.  |
The Motley Fool July 14, 2008 Brian Orelli |
Teva Gets a Taste of Its Own Medicine Momenta Pharmaceuticals and Novartis are challenging the patents on Teva Pharmaceutical's blockbuster multiple sclerosis drug Copaxone.  |
The Motley Fool June 7, 2004 Brian Gorman |
Novartis Nabs Sabex Novartis' purchase gives it a lifeline to the generics market.  |
The Motley Fool December 19, 2006 Brian Gorman |
Novartis Cuts in Line at the Drugstore Consolidation in pharmacy benefits management may leave Novartis most resistant to pricing pressure. Investors, take note.  |
The Motley Fool September 7, 2005 Rich Duprey |
Is Chiron Worth It? The vaccine maker rejects Novartis' bid of $40 a share as inadequate. How much should the pharma pay? Investors, take note.  |
Chemistry World November 1, 2012 Andrew Turley |
Novartis biotech plant for Singapore The new plant, which will make drugs through cell culture, will be located with the Novartis production plant at Tuas.  |
The Motley Fool November 12, 2009 Brian Orelli |
How Do You Say 'Drug Development' in Mandarin? Drug giant Novartis announces that it's heading to China in a big way.  |
The Motley Fool April 14, 2005 Brian Gorman |
Novartis Moves on Multiple Fronts Even with its investment in a potential blockbuster, Novartis remains remarkably diversified. Investors can rest assured, though, that the company's strategy won't leave it as vulnerable as other outfits.  |
The Motley Fool November 6, 2006 Brian Gorman |
Novartis' China Gambit Novartis probably won't get any near-term dividend from its China investment, but the nation is too big to ignore. Investors, take note.  |
Chemistry World January 24, 2013 Andrew Turley |
Vasella to leave Novartis in August Veteran pharma executive Danial Vasella has unexpectedly announced his resignation as chair of the board of directors at Novartis after 17 years at the top of the company.  |
The Motley Fool August 30, 2010 Brian Orelli |
Maybe Not a Blockbuster, But We'll Take It Novartis' newest addition, blood pressure medication Tekamlo, isn't going to rocket to the top of the 2020 best seller list, but it's still a nice addition nonetheless.  |
The Motley Fool March 16, 2006 Rich Duprey |
Chiron's Shareholder Revolt Hedge funds oppose the biotech's buyout by pharmaceutical giant Novartis. Investors, take note.  |
The Motley Fool June 22, 2007 Brian Lawler |
Novartis' Good Week The pharma receives a pair of positive regulatory decisions. Investors, take note.  |
Chemistry World February 15, 2007 Victoria Gill |
Novartis Contests India's Patent Law Swiss pharmaceutical company Novartis has accused the Indian government of failing to comply with WTO rules after it refused to grant the company a patent on its cancer drug Glivec.  |
Managed Care November 2004 |
Headlines On Deadline... What goes around comes around. At least that's what critics of the pharmaceutical industry seem to be saying as they gloat over reports that Novartis wants its employees to use more generic and over-the-counter medications.  |
The Motley Fool June 28, 2010 Brian Orelli |
The Trouble Is They're Facing a Bazooka Alcon's minority shareholders are still fighting against Novartis' takeover.  |
The Motley Fool April 24, 2006 Stephen D. Simpson |
Novartis: A Good Story Repeated Whether sales were a little light or not, this is still a high-quality pharmaceutical company. The company not only has a good pipeline, but the valuation is still attractive without needing to make particularly aggressive assumptions.  |
Chemistry World April 25, 2014 Andy Extance |
$25bn-plus trade sharpens pharma giants' focus Three leading pharmaceutical firms are set to exchange business segments valued at over $25 billion, in deals affecting at least 14,000 employees.  |